Ziprasidone in the treatment of mania in bipolar disorder

Stephen E. Nicolson, Charles Nemeroff

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Ziprasidone is an atypical antipsychotic with a unique receptor-binding profile. Currently, ziprasidone is approved by the US Food and Drug Administration for the acute treatment of psychosis in schizophrenia and mania in bipolar disorder. When compared to certain other atypical antipsychotics, ziprasidone appears to have a relatively benign side effect profile, especially as regards metabolic effects eg, weight gain, serum lipid elevations and glucose dysregulation. Taken together, these data suggest that ziprasidone may be a first line treatment for patients with bipolar mania. However, ziprasidone is a relatively new medication for which adverse events after long-term use and/or in vulnerable patient populations must be studied. Unstudied areas of particular importance include the efficacy and safety of ziprasidone in the treatment of bipolar depression and relapse prevention of mania as, well as in the subpopulations of pregnant women, the elderly and pediatric patients. The emergence of mania in patients taking ziprasidone is another topic for further study.

Original languageEnglish
Pages (from-to)823-834
Number of pages12
JournalNeuropsychiatric Disease and Treatment
Volume3
Issue number6
StatePublished - Dec 1 2007
Externally publishedYes

Fingerprint

Bipolar Disorder
Therapeutics
Antipsychotic Agents
Vulnerable Populations
United States Food and Drug Administration
Secondary Prevention
ziprasidone
Psychotic Disorders
Weight Gain
Pregnant Women
Schizophrenia
Pediatrics
Lipids
Safety
Glucose
Serum

Keywords

  • Antipsychotic
  • Bipolar disorder
  • Mania
  • Mood disorder
  • Neuroleptic
  • Ziprasidone

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Biological Psychiatry

Cite this

Ziprasidone in the treatment of mania in bipolar disorder. / Nicolson, Stephen E.; Nemeroff, Charles.

In: Neuropsychiatric Disease and Treatment, Vol. 3, No. 6, 01.12.2007, p. 823-834.

Research output: Contribution to journalArticle

@article{dbb57954d4b440ea9e739c1875f649be,
title = "Ziprasidone in the treatment of mania in bipolar disorder",
abstract = "Ziprasidone is an atypical antipsychotic with a unique receptor-binding profile. Currently, ziprasidone is approved by the US Food and Drug Administration for the acute treatment of psychosis in schizophrenia and mania in bipolar disorder. When compared to certain other atypical antipsychotics, ziprasidone appears to have a relatively benign side effect profile, especially as regards metabolic effects eg, weight gain, serum lipid elevations and glucose dysregulation. Taken together, these data suggest that ziprasidone may be a first line treatment for patients with bipolar mania. However, ziprasidone is a relatively new medication for which adverse events after long-term use and/or in vulnerable patient populations must be studied. Unstudied areas of particular importance include the efficacy and safety of ziprasidone in the treatment of bipolar depression and relapse prevention of mania as, well as in the subpopulations of pregnant women, the elderly and pediatric patients. The emergence of mania in patients taking ziprasidone is another topic for further study.",
keywords = "Antipsychotic, Bipolar disorder, Mania, Mood disorder, Neuroleptic, Ziprasidone",
author = "Nicolson, {Stephen E.} and Charles Nemeroff",
year = "2007",
month = "12",
day = "1",
language = "English",
volume = "3",
pages = "823--834",
journal = "Neuropsychiatric Disease and Treatment",
issn = "1176-6328",
publisher = "Dove Medical Press Ltd.",
number = "6",

}

TY - JOUR

T1 - Ziprasidone in the treatment of mania in bipolar disorder

AU - Nicolson, Stephen E.

AU - Nemeroff, Charles

PY - 2007/12/1

Y1 - 2007/12/1

N2 - Ziprasidone is an atypical antipsychotic with a unique receptor-binding profile. Currently, ziprasidone is approved by the US Food and Drug Administration for the acute treatment of psychosis in schizophrenia and mania in bipolar disorder. When compared to certain other atypical antipsychotics, ziprasidone appears to have a relatively benign side effect profile, especially as regards metabolic effects eg, weight gain, serum lipid elevations and glucose dysregulation. Taken together, these data suggest that ziprasidone may be a first line treatment for patients with bipolar mania. However, ziprasidone is a relatively new medication for which adverse events after long-term use and/or in vulnerable patient populations must be studied. Unstudied areas of particular importance include the efficacy and safety of ziprasidone in the treatment of bipolar depression and relapse prevention of mania as, well as in the subpopulations of pregnant women, the elderly and pediatric patients. The emergence of mania in patients taking ziprasidone is another topic for further study.

AB - Ziprasidone is an atypical antipsychotic with a unique receptor-binding profile. Currently, ziprasidone is approved by the US Food and Drug Administration for the acute treatment of psychosis in schizophrenia and mania in bipolar disorder. When compared to certain other atypical antipsychotics, ziprasidone appears to have a relatively benign side effect profile, especially as regards metabolic effects eg, weight gain, serum lipid elevations and glucose dysregulation. Taken together, these data suggest that ziprasidone may be a first line treatment for patients with bipolar mania. However, ziprasidone is a relatively new medication for which adverse events after long-term use and/or in vulnerable patient populations must be studied. Unstudied areas of particular importance include the efficacy and safety of ziprasidone in the treatment of bipolar depression and relapse prevention of mania as, well as in the subpopulations of pregnant women, the elderly and pediatric patients. The emergence of mania in patients taking ziprasidone is another topic for further study.

KW - Antipsychotic

KW - Bipolar disorder

KW - Mania

KW - Mood disorder

KW - Neuroleptic

KW - Ziprasidone

UR - http://www.scopus.com/inward/record.url?scp=38149103058&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=38149103058&partnerID=8YFLogxK

M3 - Article

C2 - 19300617

AN - SCOPUS:38149103058

VL - 3

SP - 823

EP - 834

JO - Neuropsychiatric Disease and Treatment

JF - Neuropsychiatric Disease and Treatment

SN - 1176-6328

IS - 6

ER -